LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases - PubMed

Affiliations

• PMID: 10903992
• DOI: 10.1161/01.res.87.2.99

LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases

R H Böger et al. Circ Res. 2000.

Abstract

Asymmetrical dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor. It is formed by protein arginine N-methyltransferases (PRMTs), which utilize S-adenosylmethionine as methyl group donor. ADMA plasma concentration is elevated in hypercholesterolemia, leading to endothelial dysfunction and producing proatherogenic changes of endothelial cell function. Four different isoforms of human PRMTs have been identified. Because the release of ADMA from human endothelial cells is increased in the presence of native or oxidized LDL cholesterol, we investigated the potential involvement of PRMT activity and gene expression in this effect. We found that the production of ADMA by human endothelial cells is upregulated in the presence of methionine or homocysteine and inhibited by either of the methyltransferase inhibitors S-adenosylhomocysteine, adenosine dialdehyde, or cycloleucine. This effect is specific for ADMA but not symmetrical dimethylarginine. The upregulation of ADMA release by native and oxidized LDL is abolished by S-adenosylhomocysteine and by the antioxidant pyrrollidine dithiocarbamate. Furthermore, a methyl-(14)C label is transferred from S-adenosylmethionine to ADMA but not symmetrical dimethylarginine, in human endothelial cells. The expression of PRMTs is upregulated in the presence of native or oxidized LDL. Our data suggest that the production of ADMA by human endothelial cells is regulated by S-adenosylmethionine-dependent methyltransferases. This activity is upregulated by LDL cholesterol, which may be due in part to the enhanced gene expression of PRMTs. In concentrations reached by stimulation of methyltransferases (5 to 50 micromol/L), ADMA significantly inhibited the formation of (15)N-nitrite from L-[guanidino-(15)N(2)]arginine. These findings suggest a novel mechanism by which ADMA concentration is elevated in hypercholesterolemia, leading to endothelial dysfunction and atherosclerosis.

Similar articles

• Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.

  Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR. Böger RH, et al. Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1557-64. doi: 10.1161/01.atv.20.6.1557. Arterioscler Thromb Vasc Biol. 2000. PMID: 10845872

• Probucol decreases asymmetrical dimethylarginine level by alternation of protein arginine methyltransferase I and dimethylarginine dimethylaminohydrolase activity.

  Jiang JL, Zhang XH, Li NS, Rang WQ, Feng-Ye, Hu CP, Li YJ, Deng HW. Jiang JL, et al. Cardiovasc Drugs Ther. 2006 Aug;20(4):281-94. doi: 10.1007/s10557-006-9065-1. Cardiovasc Drugs Ther. 2006. PMID: 16897158

• Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level.

  Jiang JL, Li Ns NS, Li YJ, Deng HW. Jiang JL, et al. Br J Pharmacol. 2002 Mar;135(5):1175-82. doi: 10.1038/sj.bjp.0704563. Br J Pharmacol. 2002. PMID: 11877324 Free PMC article.

• Association of asymmetric dimethylarginine and endothelial dysfunction.

  Böger RH. Böger RH. Clin Chem Lab Med. 2003 Nov;41(11):1467-72. doi: 10.1515/CCLM.2003.225. Clin Chem Lab Med. 2003. PMID: 14656027 Review.

• Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).

  Maas R. Maas R. Vasc Med. 2005 Jul;10 Suppl 1:S49-57. doi: 10.1191/1358863x05vm605oa. Vasc Med. 2005. PMID: 16444869 Review.

Cited by

• Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine.

  Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, Leiper J, Cooke JP. Ghebremariam YT, et al. Circulation. 2013 Aug 20;128(8):845-53. doi: 10.1161/CIRCULATIONAHA.113.003602. Epub 2013 Jul 3. Circulation. 2013. PMID: 23825361 Free PMC article.

• Endothelial dysfunction due to eNOS uncoupling: molecular mechanisms as potential therapeutic targets.

  Janaszak-Jasiecka A, Płoska A, Wierońska JM, Dobrucki LW, Kalinowski L. Janaszak-Jasiecka A, et al. Cell Mol Biol Lett. 2023 Mar 9;28(1):21. doi: 10.1186/s11658-023-00423-2. Cell Mol Biol Lett. 2023. PMID: 36890458 Free PMC article.

• The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease.

  Sibal L, Agarwal SC, Home PD, Boger RH. Sibal L, et al. Curr Cardiol Rev. 2010 May;6(2):82-90. doi: 10.2174/157340310791162659. Curr Cardiol Rev. 2010. PMID: 21532773 Free PMC article.

• Pre-Analytical and Clinical Validation of a Dried Blood Spot Assay for Asymmetric Dimethylarginine and L-Arginine.

  Hannemann J, Roskam TI, Eilermann I, Siques P, Brito J, Böger R. Hannemann J, et al. J Clin Med. 2020 Apr 9;9(4):1072. doi: 10.3390/jcm9041072. J Clin Med. 2020. PMID: 32283799 Free PMC article.

• Novel metabolic roles of L-arginine in body energy metabolism and possible clinical applications.

  Hristina K, Langerholc T, Trapecar M. Hristina K, et al. J Nutr Health Aging. 2014;18(2):213-8. doi: 10.1007/s12603-014-0015-5. J Nutr Health Aging. 2014. PMID: 24522477

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database